Brief Summary
This is a phase 1/2, dose-escalation and cohort-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advancedat a late stage, far along solid tumors.
Intervention / Treatment
- Drug: DT-7012
- Drug: Immune checkpoint inhibitor
Inclusion Criteria:
- Histologically or cytologically confirmed solid tumor, among selected cancer types, that is recurrent, locally advanced (i.e., not eligible for curative surgery or radiotherapy) or metastatic, has progressed after at least one line of systemic therapy and has no established curative option.
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the local site investigator/radiologist.
- At least 1 tumour lesion accessible to biopsyremoval of a section of tissue to analyse for cancer cells per treating physician judgement.
- Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
- Adequate organ function.